HRP20220701T1 - Spojeni benzazepini za liječenje touretteova sindroma - Google Patents
Spojeni benzazepini za liječenje touretteova sindroma Download PDFInfo
- Publication number
- HRP20220701T1 HRP20220701T1 HRP20220701TT HRP20220701T HRP20220701T1 HR P20220701 T1 HRP20220701 T1 HR P20220701T1 HR P20220701T T HRP20220701T T HR P20220701TT HR P20220701 T HRP20220701 T HR P20220701T HR P20220701 T1 HRP20220701 T1 HR P20220701T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- treatment
- tourette
- syndrome
- Prior art date
Links
- 208000000323 Tourette Syndrome Diseases 0.000 title claims 3
- 208000016620 Tourette disease Diseases 0.000 title claims 3
- 150000008038 benzoazepines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 16
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- DMJWENQHWZZWDF-PKOBYXMFSA-N (6aS,13bR)-11-chloro-7-methyl-5,6,6a,8,9,13b-hexahydronaphtho[1,2-a][3]benzazepin-12-ol Chemical compound CN1CCC2=CC(Cl)=C(O)C=C2[C@H]2C3=CC=CC=C3CC[C@H]12 DMJWENQHWZZWDF-PKOBYXMFSA-N 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229950009714 ecopipam Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (9)
1. Spoj za uporabu u liječenju Tourettovog sindroma kod ljudi, naznačen time što je spoj ekopipam ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, pri čemu je spoj za oralnu primjenu u dozi od 50 mg do 100 mg/dan.
2. Spoj za uporabu prema zahtjevu 1, naznačen time što subjekt nije stariji od 17 godina.
3. Spoj za uporabu prema zahtjevima 1 do 2, naznačen time što se smatra da subjekt nema poremećaj pažnje i hiperaktivnosti, depresiju, i opsesivno-kompulzivni poremećaj.
4. Spoj za uporabu prema zahtjevima 1 do 3, naznačen time što je spoj formuliran za oralnu primjenu.
5. Spoj za uporabu prema zahtjevu 1, naznačen time što se davanje spoja ponavlja jednom, dvaput, ili tri puta dnevno.
6. Spoj za uporabu prema zahtjevima 1-5 za uporabu u kombinaciji s drugim liječenjem kao što je bihevioralna, kirurška, ili farmaceutska terapija za liječenje Touretteovog sindroma.
7. Spoj za uporabu prema zahtjevima 1-2, ili 4-6 za uporabu u kombinaciji s terapeutski učinkovitom količinom drugog spoja za liječenje poremećaja pažnje i hiperaktivnosti, depresije, ili opsesivno-kompulzivnog poremećaja.
8. Spoj za uporabu prema zahtjevu 1, naznačen time što je spoj formuliran u obliku jedinične doze.
9. Spoj za uporabu prema zahtjevu 1, naznačen time što je spoj formuliran kao kapsula, tableta, pilule, prah, ili sirup, ili za brzo, produženo, ili odgođeno otpuštanje.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261671044P | 2012-07-12 | 2012-07-12 | |
| PCT/US2013/050337 WO2014012034A1 (en) | 2012-07-12 | 2013-07-12 | Fused benzazepines for treatment of tourette's syndrome |
| EP13815988.4A EP2872145B8 (en) | 2012-07-12 | 2013-07-12 | Fused benzazepines for treatment of tourette's syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220701T1 true HRP20220701T1 (hr) | 2022-07-08 |
Family
ID=49916578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220701TT HRP20220701T1 (hr) | 2012-07-12 | 2013-07-12 | Spojeni benzazepini za liječenje touretteova sindroma |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11298361B2 (hr) |
| EP (2) | EP2872145B8 (hr) |
| JP (1) | JP6181754B2 (hr) |
| KR (1) | KR20150029713A (hr) |
| CN (1) | CN104540510A (hr) |
| AU (1) | AU2013289922B2 (hr) |
| CA (1) | CA2879020C (hr) |
| DK (1) | DK2872145T3 (hr) |
| ES (1) | ES2914043T3 (hr) |
| HK (1) | HK1209336A1 (hr) |
| HR (1) | HRP20220701T1 (hr) |
| HU (1) | HUE058696T2 (hr) |
| IL (4) | IL292725A (hr) |
| LT (1) | LT2872145T (hr) |
| PL (1) | PL2872145T3 (hr) |
| PT (1) | PT2872145T (hr) |
| RS (1) | RS63266B1 (hr) |
| SI (1) | SI2872145T1 (hr) |
| WO (1) | WO2014012034A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3057595T3 (da) | 2013-10-18 | 2020-08-10 | Emalex Biosciences Inc | Smeltebenzazepiner til behandling af stammen |
| EP3833351A4 (en) * | 2018-09-20 | 2021-10-13 | Ovid Therapeutics Inc. | USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4477378A (en) | 1980-02-05 | 1984-10-16 | Schering Corp. | Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines |
| US4973586A (en) | 1986-01-16 | 1990-11-27 | Schering Corporation | Fused benzazepines, compositions of, and medical use thereof |
| US5302716A (en) | 1986-01-16 | 1994-04-12 | Schering Corporation | Fused benzazepines |
| BE1005064A4 (nl) | 1991-07-03 | 1993-04-06 | Asm Fico Tooling | Buiginrichting. |
| GB9127306D0 (en) | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
| ATE201680T1 (de) | 1994-03-16 | 2001-06-15 | Cenes Ltd | 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze |
| US5607967A (en) | 1994-10-27 | 1997-03-04 | Merck & Co., Inc. | Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid |
| CN1283116A (zh) | 1997-10-28 | 2001-02-07 | 先灵公司 | 降低哺乳动物嗜欲的方法 |
| AR018297A1 (es) * | 1998-03-02 | 2001-11-14 | Schering Corp | Uso de un antagonista d1/d5 para la manufactura de un medicamento para tratar desordenes compulsivos obsesivos, desordenes somatoformes, desordenesdisociativos, desordenes al comer, desordenes de control de impulso y autismo |
| US6132724A (en) | 1998-04-29 | 2000-10-17 | City Of Hope National Medical Center | Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| AU2002354041A1 (en) | 2001-11-06 | 2003-05-19 | John L. Haracz | Antimnemonic therapy for hypermemory syndromes |
| US8518933B2 (en) | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
| WO2011057199A1 (en) | 2009-11-06 | 2011-05-12 | Adenios, Inc. | Compositions for treating cns disorders |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2012033874A1 (en) | 2010-09-10 | 2012-03-15 | Chipkin Richard E | Method of treating compulsive self-injurious behaviors |
| DK3057595T3 (da) | 2013-10-18 | 2020-08-10 | Emalex Biosciences Inc | Smeltebenzazepiner til behandling af stammen |
-
2013
- 2013-07-12 CA CA2879020A patent/CA2879020C/en active Active
- 2013-07-12 HU HUE13815988A patent/HUE058696T2/hu unknown
- 2013-07-12 DK DK13815988.4T patent/DK2872145T3/da active
- 2013-07-12 EP EP13815988.4A patent/EP2872145B8/en active Active
- 2013-07-12 WO PCT/US2013/050337 patent/WO2014012034A1/en active Application Filing
- 2013-07-12 LT LTEPPCT/US2013/050337T patent/LT2872145T/lt unknown
- 2013-07-12 CN CN201380036903.9A patent/CN104540510A/zh active Pending
- 2013-07-12 HR HRP20220701TT patent/HRP20220701T1/hr unknown
- 2013-07-12 ES ES13815988T patent/ES2914043T3/es active Active
- 2013-07-12 JP JP2015521856A patent/JP6181754B2/ja active Active
- 2013-07-12 IL IL292725A patent/IL292725A/en unknown
- 2013-07-12 SI SI201331993T patent/SI2872145T1/sl unknown
- 2013-07-12 KR KR1020157001403A patent/KR20150029713A/ko not_active Application Discontinuation
- 2013-07-12 PL PL13815988T patent/PL2872145T3/pl unknown
- 2013-07-12 EP EP21170063.8A patent/EP3919060A1/en active Pending
- 2013-07-12 US US14/414,368 patent/US11298361B2/en active Active
- 2013-07-12 PT PT138159884T patent/PT2872145T/pt unknown
- 2013-07-12 AU AU2013289922A patent/AU2013289922B2/en active Active
- 2013-07-12 IL IL300144A patent/IL300144A/en unknown
- 2013-07-12 RS RS20220519A patent/RS63266B1/sr unknown
-
2014
- 2014-12-23 IL IL236403A patent/IL236403A0/en unknown
-
2015
- 2015-10-14 HK HK15110081.2A patent/HK1209336A1/xx unknown
-
2021
- 2021-05-21 US US17/327,465 patent/US20210275540A1/en not_active Abandoned
- 2021-07-05 IL IL284615A patent/IL284615A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL236403A0 (en) | 2015-02-26 |
| PT2872145T (pt) | 2022-05-26 |
| SI2872145T1 (sl) | 2022-07-29 |
| US11298361B2 (en) | 2022-04-12 |
| LT2872145T (lt) | 2022-06-27 |
| WO2014012034A1 (en) | 2014-01-16 |
| RS63266B1 (sr) | 2022-06-30 |
| IL292725A (en) | 2022-07-01 |
| CN104540510A (zh) | 2015-04-22 |
| JP2015522082A (ja) | 2015-08-03 |
| US20210275540A1 (en) | 2021-09-09 |
| EP2872145A4 (en) | 2015-12-02 |
| CA2879020C (en) | 2021-02-09 |
| EP2872145A1 (en) | 2015-05-20 |
| JP6181754B2 (ja) | 2017-08-16 |
| AU2013289922B2 (en) | 2016-12-15 |
| DK2872145T3 (da) | 2022-06-13 |
| ES2914043T3 (es) | 2022-06-07 |
| HK1209336A1 (en) | 2016-04-01 |
| IL284615A (en) | 2021-08-31 |
| HUE058696T2 (hu) | 2022-09-28 |
| CA2879020A1 (en) | 2014-01-16 |
| IL300144A (en) | 2023-03-01 |
| KR20150029713A (ko) | 2015-03-18 |
| US20150164911A1 (en) | 2015-06-18 |
| EP2872145B8 (en) | 2022-04-13 |
| EP2872145B1 (en) | 2022-03-09 |
| PL2872145T3 (pl) | 2022-06-20 |
| AU2013289922A1 (en) | 2015-01-29 |
| EP3919060A1 (en) | 2021-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523407A5 (hr) | ||
| JP2016147915A5 (hr) | ||
| JP2016501828A5 (hr) | ||
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| JP2015038135A5 (hr) | ||
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| JP2013231087A5 (hr) | ||
| GB2495676A (en) | Use of binders for manufacturing storage stable formulations | |
| JP2012193216A5 (hr) | ||
| JP2015532296A5 (hr) | ||
| MX340188B (es) | Elaboracion de granulos sin activos y tabletas que comprenden los mismos. | |
| IL215826A (en) | Pharmaceutical preparation with delayed release, process of preparation of the preparation, use of the preparation for the preparation of pain medication and the pill containing it. | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| PH12014501408A1 (en) | Immediate release multi unit pellet system | |
| MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
| JP2013541583A5 (hr) | ||
| HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru | |
| BR112013012100A2 (pt) | composição ou formulação farmacêutica adaptada para administração oral em forma de comprimido, comprimido revestido ou cápsula na prevenção ou tratamento de distúrbios intestinais, processo para preparar a composição ou formulação farmacêutica e uso da composição ou formulação farmacêutica | |
| WO2014144407A8 (en) | Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof | |
| HRP20220701T1 (hr) | Spojeni benzazepini za liječenje touretteova sindroma | |
| SA516370446B1 (ar) | تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها | |
| MX2018010065A (es) | Forma de dosificacion oral que comprende rifaximina en forma beta. | |
| JP2016528283A5 (hr) | ||
| MX2018011293A (es) | Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma. |